Dr. Antoinette Perry
Chief Scientific Officer
Associate Professor Antoinette Perry is Head of Cell and Molecular Biology in University College Dublin’s College of Science and Co-Director of its Cancer Biology & Therapeutics Laboratory. Her specialism is translational cancer epigenomics - understanding the role of epigenetic aberrations in the pathogenesis of cancer and harnessing these aberrations to develop prognostic and predictive biomarkers. Prof. Perry has a B.A. in Human Genetics (Trinity College Dublin, 2001) and a Ph.D. in prostate cancer epigenetics (Trinity College Dublin, 2007). She continued her post-doctoral research in TCD, before taking an academic faculty position from 2015 in UCD.
Chief Executive Officer
Kevin Tansley is an experienced medical diagnostic executive. Former CFO and Board member of a NASDAQ-listed company, including strategic planning and managing international operations in the USA and Europe. Strong transactional skills through a variety of acquisitions, divestitures, investment projects and equity/debt fundraisings in the healthcare and electricity sectors. Strong emphasis on managing relationships with key stakeholders, including institutional equity investors and a range of debt providers.
Chief Financial Officer & Chief Operating Officer
Edward Simons is a former investment banker who has worked in a range of roles in financial services in the UK, including client-facing functions, sector coverage, business development, product origination, transaction execution, head office and front office support functions. He has significant experience in fund raising in the USA private placement and high yield debt markets. He is a Fellow of Chartered Accountants Ireland.
Dr. Marie Eagleton
Chief Technical Officer
Dr Marie Eagleton (CTO) is a Biochemistry graduate with a postgraduate Ph.D. in Immunology. She has senior management experience in the medical device industry, laboratory diagnostics and research, covering product development, regulation, commercialisation, development and transfer-to-manufacture of new biotech products.
Dr. Robert Passas
Chief Commercial Officer
Dr. Robert Passas is a seasoned international business professional in life sciences and healthcare, having held senior commercial leadership roles (Abbott Diagnostics, Quidel, Chembio, The Binding Site) where he has launched and grown product lines in key markets. He has a Doctorate in Analytical chemistry – clinical research in diabetes and novel diagnostics.
Dr. Jim Walsh
Dr. Walsh has 25 years general management experience in the healthcare industry with particular experience in diagnostics. He is a Director of Trinity Biotech, (NASDAQ : TRIB) and is Executive Chairman of Novus Diagnostics Ltd. Previously Dr. Walsh was Executive Chairman of GenCell Biosystems Ltd, a Genomics platform company, acquired by Becton Dickenson in October 2014. Until 2010 Dr. Walsh was CEO of Stokes Bio Ltd. a company specialising in the area of Molecular Diagnostics, acquired by Life Technologies. Dr. Walsh is also an investor in and a Director of a number of early stage life science companies.